Menactra SC Injection 0.5 ml/vial Uses, Dosage, Side Effects and more
The presence of bactericidal anti-capsular meningococcal antibodies has been associated with protection from invasive meningococcal disease. Menactra induces the production of bactericidal antibodies specific to the capsular polysaccharides of serogroups A, C, Y and W-135.
| Trade Name | Menactra SC Injection 0.5 ml/vial |
| Generic | Polysaccharide Diphtheria Toxoid Conjugate Vaccine |
| Weight | 0.5 ml/vial |
| Type | SC Injection |
| Therapeutic Class | Vaccines, Anti-sera & Immunoglobulin |
| Manufacturer | Synovia Pharma PLC. |
| Available Country | Bangladesh |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
Menactra SC Injection 0.5 ml/vial is used for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135. This vaccine is approved for use in individuals 9 months through 55 years of age. Menactra does not prevent N meningitidis serogroup B disease.
Dosage
Primary Vaccination:
- Children 9 through 23 months of age: Two doses, three months apart.
- Individuals 2 through 55 years of age: A single dose.
- A single booster dose may be given to individuals 15 through 55 years of age at continued risk for meningococcal disease, if at least 4 years have elapsed since the prior dose.
Side Effects
Common solicited adverse events in infants and toddlers 9 and 12 months of age were injection site tenderness, erythema, and swelling; irritability, abnormal crying, drowsiness, appetite loss, vomiting, and fever
Precaution
Persons previously diagnosed with Guillain-Barre syndrome (GBS) may be at increased risk of GBS following receipt of Menactra. The decision to give Menactra should take into account the potential benefits and risks.
Interaction
When Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) are to be administered to children 4 through 6 years of age, preference should be given to simultaneous administration of the 2 vaccines or administration of Menactra prior to Menactra SC Injection 0.5 ml/vial. Administraton of Menactra one month after Menactra SC Injection 0.5 ml/vial has been shown to reduce meningococcal antibody responses to Menactra
Pneumococcal antibody responses to some serotypes in Prevnar (PCV7) were decreased following co-administration of Menactra and PCV7.
Pregnancy & Breastfeeding use
Safety and effectiveness of Menactra SC Injection 0.5 ml/vial have not been established in children younger than 9 months of age, pregnant women, nursing mothers, and adults older than 55 years of age.
Contraindication
Severe allergic reaction (eg, anaphylaxis) after a previous dose of a meningococcal capsular polysaccharide-, diphtheria toxoid- or CRM 197-containing vaccine, or to any component of Menactra
Storage Condition
Store at 2° to 8°C
